131 related articles for article (PubMed ID: 36050448)
1. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Nader-Marta G; Debien V; Eiger D; Tsourti Z; Caparica R; Kassapian M; Napoleone S; Hultsch S; Korde L; Wang Y; Chumsri S; Pritchard KI; Untch M; Bellet-Ezquerra M; Dornelles Rosa D; Moreno-Aspitia A; Piccart M; Dafni U; de Azambuja E
Br J Cancer; 2022 Nov; 127(10):1799-1807. PubMed ID: 36050448
[TBL] [Abstract][Full Text] [Related]
2. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
3. The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Martins-Branco D; Kassapian M; Debien V; Caparica R; Eiger D; Dafni U; Andriakopoulou C; El-Abed S; Ellard SL; Izquierdo M; Vicente M; Chumsri S; Piccart-Gebhart M; Moreno-Aspitia A; Knop AS; Lombard J; de Azambuja E
Breast Cancer Res Treat; 2024 Feb; 203(3):497-509. PubMed ID: 37938495
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
5. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
Moreno-Aspitia A; Holmes EM; Jackisch C; de Azambuja E; Boyle F; Hillman DW; Korde L; Fumagalli D; Izquierdo MA; McCullough AE; Wolff AC; Pritchard KI; Untch M; Guillaume S; Ewer MS; Shao Z; Sim SH; Aziz Z; Demetriou G; Mehta AO; Andersson M; Toi M; Lang I; Xu B; Smith IE; Barrios CH; Baselga J; Gelber RD; Piccart-Gebhart M;
Eur J Cancer; 2021 May; 148():287-296. PubMed ID: 33765513
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
[TBL] [Abstract][Full Text] [Related]
7. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
[TBL] [Abstract][Full Text] [Related]
8. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
9. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
10. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig GW; Royce ME; Hunt KK
JAMA Oncol; 2019 Jan; 5(1):45-50. PubMed ID: 30193295
[TBL] [Abstract][Full Text] [Related]
11. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Lambertini M; Agbor-Tarh D; Metzger-Filho O; Ponde NF; Poggio F; Hilbers FS; Korde LA; Chumsri S; Werner O; Del Mastro L; Caparica R; Moebus V; Moreno-Aspitia A; Piccart MJ; de Azambuja E
ESMO Open; 2020 Nov; 5(6):e000979. PubMed ID: 33154022
[TBL] [Abstract][Full Text] [Related]
14. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
Conte P; Frassoldati A; Bisagni G; Brandes AA; Donadio M; Garrone O; Piacentini F; Cavanna L; Giotta F; Aieta M; Gebbia V; Molino A; Musolino A; Ferro A; Maltoni R; Danese S; Zamagni C; Rimanti A; Cagossi K; Russo A; Pronzato P; Giovanardi F; Moretti G; Lombardo L; Schirone A; Beano A; Amaducci L; Bajardi EA; Vicini R; Balduzzi S; D'Amico R; Guarneri V
Ann Oncol; 2018 Dec; 29(12):2328-2333. PubMed ID: 30219886
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Eiger D; Pondé NF; Agbor-Tarh D; Moreno-Aspitia A; Piccart M; Hilbers FS; Werner O; Chumsri S; Dueck A; Kroep JR; Gomez H; Láng I; Rodeheffer RJ; Ewer MS; Suter T; de Azambuja E
Br J Cancer; 2020 May; 122(10):1453-1460. PubMed ID: 32203207
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
Krop IE; Im SA; Barrios C; Bonnefoi H; Gralow J; Toi M; Ellis PA; Gianni L; Swain SM; Im YH; De Laurentiis M; Nowecki Z; Huang CS; Fehrenbacher L; Ito Y; Shah J; Boulet T; Liu H; Macharia H; Trask P; Song C; Winer EP; Harbeck N
J Clin Oncol; 2022 Feb; 40(5):438-448. PubMed ID: 34890214
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
